Back to dashboard
All PlansCoverageMedium impact

Therapeutic Radiopharmaceuticals for Neuroendocrine Tumors

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Nuclear Medicine, Endocrinology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy establishes coverage criteria for therapeutic radiopharmaceuticals, specifically Lutetium 177 dotatate, for treating neuroendocrine tumors and pheochromocytoma/paraganglioma. The policy provides detailed background on these rare conditions and treatment approaches but does not specify the actual coverage criteria or billing requirements.

Action Required

Action needed
Review complete policy document to understand coverage criteria and prior authorization requirements for Lutetium 177 dotatate treatments. Contact BCBS MS for specific billing guidelines and required documentation for neuroendocrine tumor treatments. Update staff on rare tumor treatment protocols if your practice treats oncology patients.

Related policy hubs